GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Cyclically Adjusted PB Ratio

Omeros (FRA:3O8) Cyclically Adjusted PB Ratio : (As of May. 15, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Omeros Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Omeros Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Omeros's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Cyclically Adjusted PB Ratio Chart

Omeros Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Omeros Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Omeros's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Omeros's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omeros's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Omeros's Cyclically Adjusted PB Ratio falls into.



Omeros Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Omeros's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Omeros's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.375/129.4194*129.4194
=-0.375

Current CPI (Dec. 2023) = 129.4194.

Omeros Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.111 99.695 0.144
201406 -0.230 100.560 -0.296
201409 -0.606 100.428 -0.781
201412 -1.012 99.070 -1.322
201503 0.534 99.621 0.694
201506 0.187 100.684 0.240
201509 -0.211 100.392 -0.272
201512 -0.633 99.792 -0.821
201603 -0.935 100.470 -1.204
201606 -1.110 101.688 -1.413
201609 -0.473 101.861 -0.601
201612 -0.810 101.863 -1.029
201703 -1.024 102.862 -1.288
201706 -1.098 103.349 -1.375
201709 0.161 104.136 0.200
201712 -0.049 104.011 -0.061
201803 -0.491 105.290 -0.604
201806 -0.994 106.317 -1.210
201809 -1.556 106.507 -1.891
201812 -1.796 105.998 -2.193
201903 -2.185 107.251 -2.637
201906 -2.344 108.070 -2.807
201909 -2.565 108.329 -3.064
201912 -1.810 108.420 -2.161
202003 -2.189 108.902 -2.601
202006 -2.627 108.767 -3.126
202009 -1.203 109.815 -1.418
202012 -1.609 109.897 -1.895
202103 -2.995 111.754 -3.468
202106 -3.271 114.631 -3.693
202109 -3.570 115.734 -3.992
202112 0.336 117.630 0.370
202203 -0.071 121.301 -0.076
202206 -0.493 125.017 -0.510
202209 -0.746 125.227 -0.771
202212 1.287 125.222 1.330
202303 0.817 127.348 0.830
202306 0.301 128.729 0.303
202309 -0.208 129.860 -0.207
202312 -0.375 129.419 -0.375

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Omeros  (FRA:3O8) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Omeros Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Omeros's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Omeros (FRA:3O8) Business Description

Industry
Traded in Other Exchanges
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros (FRA:3O8) Headlines

No Headlines